Segersten Ulrika, Spector Yael, Goren Yaron, Tabak Sarit, Malmström Per-Uno
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Rosetta Genomics Ltd, Rehovot, Israel.
Urol Oncol. 2014 Jul;32(5):613-8. doi: 10.1016/j.urolonc.2013.11.001. Epub 2014 Jan 14.
To analyze microRNA profile in Ta and T1 urinary bladder cancers in combination and separately and to relate this to the risk of later developing higher-stage disease.
Formalin-fixed, paraffin-embedded samples of 44 Ta and 42 T1 bladder cancers representing cases with and without stage progression during follow-up were collected and microRNA expression levels were measured by microarray analysis.
In a comparison between the progressors and controls, in the Ta/T1 group, miR-10a-5p and miR-31-5p were differentially expressed. miR-10a-5p was also correlated to time to progression (P = 0.00012). In the subgroup analysis, 3 microRNAs, miR-10a-5p, miR-31-5p, and miR-130a-3p, were differentially expressed among Ta tumors and had a fold change of more than 1.5 (P<0.038). The comparison concerning microRNA expression between the progressors and controls in category T1 cancers revealed no significant differences.
Profiling revealed that certain microRNAs predicted the risk of developing higher-stage disease among patients with Ta cancers. Lower miR-10a-5p expression in Ta progressing tumors indicates that this microRNA could be important for later malignant potential among this group of patients.
联合及分别分析Ta期和T1期膀胱癌中的微小RNA谱,并将其与后期发展为更高分期疾病的风险相关联。
收集44例Ta期和42例T1期膀胱癌的福尔马林固定、石蜡包埋样本,这些样本代表随访期间有或无分期进展的病例,并通过微阵列分析测量微小RNA表达水平。
在进展组与对照组的比较中,在Ta/T1组中,miR-10a-5p和miR-31-5p存在差异表达。miR-10a-5p也与进展时间相关(P = 0.00012)。在亚组分析中,3种微小RNA,即miR-10a-5p、miR-31-5p和miR-130a-3p,在Ta期肿瘤中存在差异表达,且倍数变化大于1.5(P<0.038)。T1期癌症进展组与对照组之间微小RNA表达的比较未发现显著差异。
分析表明,某些微小RNA可预测Ta期癌症患者发展为更高分期疾病的风险。Ta期进展性肿瘤中miR-10a-5p表达较低表明,这种微小RNA可能对该组患者后期的恶性潜能具有重要意义。